These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11996402)

  • 1. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants.
    Young J
    Respir Med; 2002 Apr; 96 Suppl B():S31-5. PubMed ID: 11996402
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prevention of respiratory syncytial virus bronchiolitis].
    Marchac V
    Arch Pediatr; 2006 Dec; 13 Suppl 5():S12-7. PubMed ID: 17550819
    [No Abstract]   [Full Text] [Related]  

  • 3. The association between respiratory syncytial virus infection and reactive airway disease.
    Piedimonte G
    Respir Med; 2002 Apr; 96 Suppl B():S25-9. PubMed ID: 11996401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory syncytial virus prophylaxis--the story so far.
    Simoes EA; Groothuis JR
    Respir Med; 2002 Apr; 96 Suppl B():S15-24. PubMed ID: 11996400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group.
    Groothuis JR
    Pediatr Infect Dis J; 2001 Jun; 20(6):628-30. PubMed ID: 11419509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in prevention of respiratory syncytial virus infections.
    Prober CG; Sullender WM
    J Pediatr; 1999 Nov; 135(5):546-58. PubMed ID: 10547241
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.
    Null D; Pollara B; Dennehy PH; Steichen J; Sánchez PJ; Givner LB; Carlin D; Landry B; Top FH; Connor E
    Pediatr Infect Dis J; 2005 Nov; 24(11):1021-3. PubMed ID: 16282947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis against respiratory syncytial virus in premature infants. IMpact-RSV Study Group.
    Top FH; Connor EM; Carlin DA
    Lancet; 2000 Mar; 355(9208):1014. PubMed ID: 10768456
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
    Scholz H
    Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.
    Abarca K; Jung E; Fernández P; Zhao L; Harris B; Connor EM; Losonsky GA;
    Pediatr Infect Dis J; 2009 Apr; 28(4):267-72. PubMed ID: 19258920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.
    Meissner HC; Rennels MB; Pickering LK; Hall CB
    Pediatr Infect Dis J; 2004 Mar; 23(3):284-5. PubMed ID: 15014320
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of respiratory syncytial virus infection in infants.
    Handforth J; Sharland M; Friedland JS
    BMJ; 2004 May; 328(7447):1026-7. PubMed ID: 15117767
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection.
    Lanari M; Vandini S; Arcuri S; Galletti S; Faldella G
    Clin Dev Immunol; 2013; 2013():359683. PubMed ID: 23840240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.
    Committee on Infectious Diseases
    Pediatrics; 2009 Dec; 124(6):1694-701. PubMed ID: 19736258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of bronchiolitis hospitalisations and respiratory syncytial virus immunoprophylaxis in non-metropolitan Western Australia.
    Moore HC; Keil AD; Richmond PC; Lehmann D
    Med J Aust; 2009 Nov; 191(10):574. PubMed ID: 19912095
    [No Abstract]   [Full Text] [Related]  

  • 18. Respiratory syncytial virus infections: old challenges and new opportunities.
    Mejías A; Chávez-Bueno S; Jafri HS; Ramilo O
    Pediatr Infect Dis J; 2005 Nov; 24(11 Suppl):S189-96, discussion S196-7. PubMed ID: 16378045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
    Onuzo OC
    Cardiol Young; 2004 Aug; 14(4):466-7; author reply 467-9. PubMed ID: 15680062
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.